Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.63 |
| ▸ | CTSB | P07858 | 2/20 | 0.63 |
| ▸ | CTSK | P43235 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | KDM5A | P29375 | 3/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1279047 | 0.91 | CTSL (0.57) | CTSLCTSBCTSKPOLBNPSR1 | |
| SCHEMBL995119 | 0.90 | POLB (0.66) | CTSLCTSBCTSKPOLBNPSR1 | |
| SCHEMBL24371203 | 0.88 | CTSL (0.60) | CTSLCTSBCTSKPOLBNPSR1 | |
| SCHEMBL27553686 | 0.88 | CTSL (0.60) | CTSLCTSBCTSKPOLBNPSR1 | |
| SCHEMBL144377 | 0.87 | CTSL (0.54) | CTSLCTSBCTSKPOLBNPSR1 | |
| SCHEMBL5223407 | 0.87 | KDM5A (0.57) | CTSLCTSBCTSKPOLBNPSR1 | |
| SCHEMBL25403939 | 0.87 | CYP1A2 (0.57) | CTSLCTSBCTSKPOLBNPSR1 | |
| SCHEMBL25400740 | 0.87 | CYP1A2 (0.57) | CTSLCTSBCTSKPOLBNPSR1 | |
| SCHEMBL5223393 | 0.87 | KDM5A (0.57) | CTSLCTSBCTSKPOLBNPSR1 | |
| SCHEMBL27100904 | 0.87 | CYP1A2 (0.57) | CTSLCTSBCTSKPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279737-B1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-8178554-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2012-05-15 | — | — | US | disclosed |
| US-8148540-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ASTRAZENECA (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-09-01 | — | — | US | disclosed |
| EP-2279737-A1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2011-02-02 | — | — | EP | disclosed |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-01-27 | — | — | US | disclosed |
| EP-1480644-B1 | NOVEL HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA+LACTAMASES | NOVEXEL (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-7732610-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | NOVEXEL (FR) | 2010-02-25 | — | — | US | disclosed |
| CN-1655781-A | Novel heterocyclic compounds having beta-lactamase inhibitor activity | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | disclosed |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | US | disclosed |
| EP-1480644-A2 | NOVEL HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA+LACTAMASES | Aventis Pharma S.A. (FR) | 2004-12-01 | — | — | EP | disclosed |
| EP-1307457-B1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2004-04-07 | — | — | EP | disclosed |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003063864-A2 | HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | WO | disclosed |
| EP-1307457-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | Aventis Pharma S.A. (FR) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010172-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2002-02-07 | — | — | WO | disclosed |
| US-5827875-A | PYRROLIDINE DERIVATIVES; ANTIATHEROSCLEROSIS AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-27 | — | — | US | disclosed |
| WO-1997043257-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | CTSL 280/4885CTSB 246/4885CTSK 463/4885 |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | CTSL 561/4885CTSB 522/4885CTSK 720/4885 |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | CTSL 280/4885CTSB 246/4885CTSK 463/4885 |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | BACE1, GAA, CEL | CTSL 280/4885CTSB 246/4885CTSK 463/4885 |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | CTSL 561/4885CTSB 522/4885CTSK 720/4885 |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | AZI2, NISCH, DCTPP1 | CTSL 861/4885CTSB 420/4885CTSK 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.